EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer

Asa P Y Lau, Sharon S Khavkine Binstock, Kelsie L Thu iD

Cancers · 31.10.2023 · 15 (21) · 5229

DOI: 10.3390/cancers15215229 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.10.2023. Verfasst von Asa P Y Lau und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 293 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Association for the Study of Lung Cancer, Cancer Research Society, St. Michael's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The success of PD-1/PD-L1-targeted therapy in lung cancer has resulted in great enthusiasm for additional immunotherapies in development to elicit similar survival benefits, particularly in patients who do not respond to or are ineligible for PD-1 blockade. CD47 is an immunosuppressive molecule that binds SIRPα on antigen-presenting cells to regulate an innate immune checkpoint that blocks phagocytosis and subsequent activation of adaptive tumor immunity. In lung cancer, CD47 expression is associated with poor survival and tumors with EGFR mutations, which do not typically respond to PD-1 blockade. Given its prognostic relevance, its role in facilitating immune escape, and the number of agents currently in clinical development, CD47 blockade represents a promising next-generation immunotherapy for lung cancer. In this review, we briefly summarize how tumors disrupt the cancer immunity cycle to facilitate immune evasion and their exploitation of immune checkpoints like the CD47–SIRPα axis. We also discuss approved immune checkpoint inhibitors and strategies for targeting CD47 that are currently being investigated. Finally, we review the literature supporting CD47 as a promising immunotherapeutic target in lung cancer and offer our perspective on key obstacles that must be overcome to establish CD47 blockade as the next standard of care for lung cancer therapy.

Schlagwörter

Stichwörter der Autor:innen

CD47immune checkpoint inhibitorsimmunotherapynon-small cell lung cancer

Autor:innen und Institutionen

  • Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON M5B 1T8, Canada.

ORCID-Profile: Kelsie L Thu

Förderung

  • International Association for the Study of Lung Cancer
  • Cancer Research Society
  • St. Michael's Hospital
  • Canada Research Chairs
  • St. Michael’s Hospital
  • Canada Research Chairs program
  • Canadian Institutes of Health Research (CIHR)
  • Ontario Graduate Scholarship

Zitieren

APA

Lau, A. P. Y., Khavkine Binstock, S. S., & Thu, K. L. (2023). CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer. Cancers, 15(21), 5229. https://doi.org/10.3390/cancers15215229

Vancouver

Lau APY, Khavkine Binstock SS, Thu KL. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer. Cancers. 2023;15(21):5229. doi:10.3390/cancers15215229

BibTeX
@article{Lau2023,
  author = {Lau, Asa P Y and Khavkine Binstock, Sharon S and Thu, Kelsie L},
  title = {CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {21},
  pages = {5229},
  doi = {10.3390/cancers15215229}
}
Kostenlos starten →